Accera identifies genetic profile of AD sufferers with heightened response to Axona Accera.

In this current study, variances in the DNA sequences linked to the genes responsible for making insulin degrading enzyme and the pro-inflammatory cytokine interleukin-1beta were been shown to be extremely predictive for improvement in cognition among patients receiving Axona. This result was especially surprising because the majority of participants in the study were already taking one or more approved Alzheimer’s disease medicines. ‘More than two dozen clinical trials possess demonstrated that one therapies offer obvious genotype dependent clinical improvements,’ commented Dr.‘What I use medicines for is to treat very specific unwanted effects,’ said Army psychiatrist Col. George Brandt. ‘I don’t wish someone in a helpless setting in a combat environment. I want to make sure I don’t possess somebody with suicidal thoughts where many people are armed.’ More than 300,000 troops have came back from Iraq or Afghanistan with P.T.S.D., depression, traumatic brain injury or some combination of those, according to The New York Times ( Following the lead of civilian medication, the armed service has relied on medicines to treat those problems heavily, leading to more widespread use of drugs in the military than in any previous war.